19:42 , Oct 3, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Patient sample, cell culture and mouse studies suggest activating SIRT7 or promoting its expression could help treat metastatic breast cancer. In samples from metastatic breast cancer patients, levels of SIRT7 were lower...
07:00 , May 1, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Hepatic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Hepatic disease Liver disease Sirtuin 7 (SIRT7) Mouse studies suggest inhibiting SIRT7 could help treat hepatic steatosis. In mice, Sirt7 knockout decreased high-fat diet-induced hepatic lipid...
07:00 , Apr 4, 2013 |  BC Innovations  |  Cover Story

Closer to class IIa HDAC inhibitors

GlaxoSmithKline plc and its Tempero Pharmaceuticals Inc. spinout have identified selective, first-in-class compounds that bind and inhibit the catalytic domain of class IIa histone deacetylase s, 1 a not-so-well-understood subset of the target family that...
07:00 , May 24, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Sirtuin 7 (SIRT7) In vitro and mouse studies suggest inhibiting SIRT7 could help treat cancer. In vitro studies identified SIRT7 as an H3K18-specific deacetylase...
08:00 , Dec 3, 2007 |  BioCentury  |  Product Development

Sirtris muscles up

As many companies do, Sirtris Pharmaceuticals Inc. has been using a less than perfect compound to provide proof of principle for its foundational idea: that activating sirtuins will be useful for treating aging-related diseases. Last...